3.43 USD
+0.01 (+0.29%)
3.3899 USD
-0.04 (-1.17%)
Overall ABCL gets a fundamental rating of 3 out of 10. We evaluated ABCL against 57 industry peers in the Life Sciences Tools & Services industry. ABCL has a great financial health rating, but its profitability evaluates not so good. ABCL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ABCL has reported negative net income.
ABCL had a negative operating cash flow in the past year.
In multiple years ABCL reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: ABCL reported negative operating cash flow in multiple years.
1.2 Ratios
ABCL's Return On Assets of -12.66% is in line compared to the rest of the industry. ABCL outperforms 43.86% of its industry peers.
Looking at the Return On Equity, with a value of -17.81%, ABCL is in line with its industry, outperforming 50.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.66% | ||
| ROE | -17.81% | ||
| ROIC | N/A |
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ABCL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABCL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABCL has been increased compared to 5 years ago.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 1.49, we must say that ABCL is in the distress zone and has some risk of bankruptcy.
ABCL has a Altman-Z score of 1.49. This is comparable to the rest of the industry: ABCL outperforms 40.35% of its industry peers.
ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.49 |
ROIC/WACCN/A
WACC9.87%
2.3 Liquidity
A Current Ratio of 10.10 indicates that ABCL has no problem at all paying its short term obligations.
ABCL has a Current ratio of 10.10. This is amongst the best in the industry. ABCL outperforms 92.98% of its industry peers.
ABCL has a Quick Ratio of 10.10. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.10, ABCL belongs to the top of the industry, outperforming 92.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.1 | ||
| Quick Ratio | 10.1 |
3. Growth
3.1 Past
ABCL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.56%.
Looking at the last year, ABCL shows a small growth in Revenue. The Revenue has grown by 7.16% in the last year.
Measured over the past years, ABCL shows a quite strong growth in Revenue. The Revenue has been growing by 19.97% on average per year.
EPS 1Y (TTM)6.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%37.62%
3.2 Future
The Earnings Per Share is expected to grow by 17.32% on average over the next years. This is quite good.
ABCL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.85% yearly.
EPS Next Y-22.09%
EPS Next 2Y-14.07%
EPS Next 3Y-5.44%
EPS Next 5Y17.32%
Revenue Next Year12.29%
Revenue Next 2Y11.18%
Revenue Next 3Y9.09%
Revenue Next 5Y44.85%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ABCL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABCL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ABCL's earnings are expected to decrease with -5.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.07%
EPS Next 3Y-5.44%
5. Dividend
5.1 Amount
ABCL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
3.43
+0.01 (+0.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners37.61%
Inst Owner Change0%
Ins Owners4.29%
Ins Owner Change-0.29%
Market Cap1.03B
Revenue(TTM)35.32M
Net Income(TTM)-171.68M
Analysts81.43
Price Target10.03 (192.42%)
Short Float %21.89%
Short Ratio12.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.37%
Min EPS beat(2)-10.38%
Max EPS beat(2)29.13%
EPS beat(4)2
Avg EPS beat(4)11.26%
Min EPS beat(4)-10.38%
Max EPS beat(4)29.86%
EPS beat(8)4
Avg EPS beat(8)4.7%
EPS beat(12)6
Avg EPS beat(12)-140.57%
EPS beat(16)8
Avg EPS beat(16)-100.23%
Revenue beat(2)2
Avg Revenue beat(2)111.14%
Min Revenue beat(2)48.58%
Max Revenue beat(2)173.69%
Revenue beat(4)2
Avg Revenue beat(4)35.69%
Min Revenue beat(4)-44.84%
Max Revenue beat(4)173.69%
Revenue beat(8)3
Avg Revenue beat(8)10.63%
Revenue beat(12)3
Avg Revenue beat(12)-3.37%
Revenue beat(16)6
Avg Revenue beat(16)1.83%
PT rev (1m)-3.6%
PT rev (3m)5.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.1%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 29.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.07 | ||
| P/tB | 1.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.12
BVpS3.22
TBVpS2.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.66% | ||
| ROE | -17.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 204.04% | ||
| Cap/Sales | 137.47% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.1 | ||
| Quick Ratio | 10.1 | ||
| Altman-Z | 1.49 |
F-Score5
WACC9.87%
ROIC/WACCN/A
Cap/Depr(3y)221.53%
Cap/Depr(5y)274.86%
Cap/Sales(3y)163.57%
Cap/Sales(5y)102.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
EPS Next Y-22.09%
EPS Next 2Y-14.07%
EPS Next 3Y-5.44%
EPS Next 5Y17.32%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%37.62%
Revenue Next Year12.29%
Revenue Next 2Y11.18%
Revenue Next 3Y9.09%
Revenue Next 5Y44.85%
EBIT growth 1Y15.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.14%
EBIT Next 3Y6.86%
EBIT Next 5Y5.3%
FCF growth 1Y-122.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1660.48%
OCF growth 3YN/A
OCF growth 5YN/A
ABCELLERA BIOLOGICS INC / ABCL FAQ
What is the ChartMill fundamental rating of ABCELLERA BIOLOGICS INC (ABCL) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ABCL.
What is the valuation status for ABCL stock?
ChartMill assigns a valuation rating of 0 / 10 to ABCELLERA BIOLOGICS INC (ABCL). This can be considered as Overvalued.
Can you provide the profitability details for ABCELLERA BIOLOGICS INC?
ABCELLERA BIOLOGICS INC (ABCL) has a profitability rating of 1 / 10.
How financially healthy is ABCELLERA BIOLOGICS INC?
The financial health rating of ABCELLERA BIOLOGICS INC (ABCL) is 7 / 10.
Can you provide the expected EPS growth for ABCL stock?
The Earnings per Share (EPS) of ABCELLERA BIOLOGICS INC (ABCL) is expected to decline by -22.09% in the next year.